NASDAQ:OVID - Ovid Therapeutics Stock Price, News & Analysis

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.08. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Ovid Therapeutics.

6 brokerages have issued 12-month price targets for Ovid Therapeutics' shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' share price to reach $14.80 in the next year. This suggests a possible upside of 557.8% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

News stories about OVID stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ovid Therapeutics earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 426,400 shares, an increase of 10.8% from the July 31st total of 384,800 shares. Based on an average trading volume of 288,800 shares, the short-interest ratio is presently 1.5 days. Currently, 2.3% of the shares of the stock are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include AC Immune (ACIU), Cyclerion Therapeutics (CYCN), OptiNose (OPTN), Forty Seven (FTSV), Avid Bioservices (CDMO), Theratechnologies (THERF), Albireo Pharma (ALBO), BIOFRONTERA AG/ADR (BFRA), Kindred Biosciences (KIN), Minerva Neurosciences (NERV), Atreca (BCEL), Assembly Biosciences (ASMB), OvaScience (OVAS), Ardelyx (ARDX) and Lexicon Pharmaceuticals (LXRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Marinus Pharmaceuticals (MRNS), Verastem (VSTM), Anavex Life Sciences (AVXL), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.84%), Cowen Inc. (2.51%), Cowen Inc. (2.51%), Renaissance Technologies LLC (1.22%), Wells Fargo & Company MN (1.14%) and Acadian Asset Management LLC (0.55%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Cowen Inc., Cowen Inc., Morgan Stanley, Charles Schwab Investment Management Inc., JPMorgan Chase & Co. and Northern Trust Corp. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, Paloma Partners Management Co, Acadian Asset Management LLC and Jane Street Group LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $2.25.

Ovid Therapeutics has a market capitalization of $87.05 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]